ImmunoPET imaging of Trop2 in patients with solid tumours
In: EMBO Molecular Medicine, Jg. 16 (2024), Heft 5, S. 1143-1161
Online
academicJournal
Zugriff:
Abstract Accurately predicting and selecting patients who can benefit from targeted or immunotherapy is crucial for precision therapy. Trophoblast cell surface antigen 2 (Trop2) has been extensively investigated as a pan-cancer biomarker expressed in various tumours and plays a crucial role in tumorigenesis through multiple signalling pathways. Our laboratory successfully developed two 68Ga-labelled nanobody tracers that can rapidly and specifically target Trop2. Of the two tracers, [68Ga]Ga-NOTA-T4, demonstrated excellent pharmacokinetics in preclinical mouse models and a beagle dog. Moreover, [68Ga]Ga-NOTA-T4 immuno-positron emission tomography (immunoPET) allowed noninvasive visualisation of Trop2 heterogeneous and differential expression in preclinical solid tumour models and ten patients with solid tumours. [68Ga]Ga-NOTA-T4 immunoPET could facilitate clinical decision-making through patient stratification and response monitoring during Trop2-targeted therapies.
Titel: |
ImmunoPET imaging of Trop2 in patients with solid tumours
|
---|---|
Autor/in / Beteiligte Person: | Huang, Wei ; Zhang, You ; Cao, Min ; Wu, Yanfei ; Jiao, Feng ; Chu, Zhaohui ; Zhou, Xinyuan ; Li, Lianghua ; Xu, Dongsheng ; Pan, Xinbing ; Guan, Yihui ; Huang, Gang ; Liu, Jianjun ; Xie, Fang ; Wei, Weijun |
Link: | |
Zeitschrift: | EMBO Molecular Medicine, Jg. 16 (2024), Heft 5, S. 1143-1161 |
Veröffentlichung: | Springer Nature, 2024 |
Medientyp: | academicJournal |
ISSN: | 1757-4684 (print) |
DOI: | 10.1038/s44321-024-00059-5 |
Schlagwort: |
|
Sonstiges: |
|